Bausch + Lomb (BLCO) Status update summary

Glaucoma market opportunity and unmet needs

• Glaucoma is a chronic neurodegenerative disease, often undetected until late stages, leading to irreversible vision loss in about 35% of patients.

• Early intervention is critical, as new diagnostic tools allow detection before functional vision loss occurs.

• There is a major unmet need for therapies that address neurodegeneration, not just intraocular pressure (IOP) reduction.

BL1107: Novel neuroprotective glaucoma therapy

• BL1107 is a next-generation alpha-2B agonist designed to lower IOP and provide neuroprotection, potentially creating a new class of glaucoma therapy.

• BL1107 targets neurodegenerative vision loss, offering rapid neurofunctional enhancement and long-term neuroprotection, with clinical proof-of-concept showing significant vision gains.

• Phase 2 results are expected in the second half of 2026, with Phase 3 targeted for 2027.

• BL1107 demonstrates superior retinal penetration and selective alpha-2B agonism, with a prodrug design that differentiates it from existing drugs.

• Patent protection extends to 2046, with sustained-release formulations and indication expansion in development; peak sales estimated at ~$0.8B.

ELIOS: Excimer laser MIGS for glaucoma

• ELIOS is an implant-free, minimally invasive excimer laser procedure that creates microchannels in the trabecular meshwork to enhance outflow and lower IOP.

• Pivotal U.S. study met primary endpoints, with over 20% sustained IOP reduction, 76% of patients achieving at least 20% IOP reduction, and 82% medication-free at 23 months.

• Eight-year EU data and 12 clinical studies confirm long-term durability, safety, and up to 81% medication-free rate at one year.

• No intraoperative complications and adverse event rates similar to cataract surgery alone.

• U.S. approval is expected in the second half of 2026, with peak sales potential of ~$175M and anticipated rapid market uptake.